Last $66.21 USD
Change Today +1.86 / 2.89%
Volume 4.7M
ABBV On Other Exchanges
Symbol
Exchange
New York
EN Paris
Mexico
Frankfurt
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
$64.75
Previous Close
$64.35
Day High
$66.95
Day Low
$64.75
52 Week High
12/8/14 - $70.76
52 Week Low
04/11/14 - $45.50
Market Cap
105.5B
Average Volume 10 Days
9.0M
EPS TTM
$3.03
Shares Outstanding
1.6B
EX-Date
01/13/15
P/E TM
21.8x
Dividend
$1.96
Dividend Yield
2.51%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. It has a strategic collaboration with Infinity Pharmaceuticals, Inc.; and a research and development collaboration with California Life Sciences LLC. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.

25,000 Employees
Last Reported Date: 11/7/14
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $790.0K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $710.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $900.0K
Senior Vice President of Human Resources
Total Annual Compensation: $545.0K
Compensation as of Fiscal Year 2013.

abbvie inc (ABBV) Key Developments

AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. VIEKIRA PAK is the only FDA-approved regimen that contains three distinct mechanisms of action - NS5A inhibitor, NS3/4A protease inhibitor and a non-nucleoside NS5B polymerase inhibitor - that work together to attack the virus at three separate stages of the disease lifecycle to inhibit it from reproducing. The approval of VIEKIRA PAK is supported by a robust clinical development program designed to study the safety and efficacy of the regimen in more than 2,300 enrolled patients across 25 countries. The program consisted of six pivotal Phase 3 studies, which demonstrated that VIEKIRA PAK cured 95%-100% of GT1a and GT1b hepatitis C patients, including patients new and experienced to treatment, and patients with compensated cirrhosis, with less than 2% of patients experiencing virological failure. Additionally, more than 98% of patients in clinical trials completed a full course of therapy.

AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) at the American Society of Hematology's 56th Annual Meeting

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells. In the study, the venetoclax group showed an overall response rate (ORR) of 15.5%, with one patient achieving a complete response and four patients achieving a complete response with incomplete blood count recovery. A complete response (CR) is sometimes called complete remission, and refers to the disappearance of all signs of cancer in response to cancer treatment. A complete response with incomplete blood count recovery (CRi) is when a patient fulfills most – but not all – criteria to be classified as a complete response. CRi indicates activity but is not the same as a complete response.

Medicines Patent Pool Signs Licensing Agreement with AbbVie Inc. for Hiv Paediatric Formulations of Lopinavir, Ritonavir

On World AIDS Day, the Medicines Patent Pool (MPP) and AbbVie announced a licensing agreement for lopinavir (LPV) and ritonavir (r), top World Health Organization-recommended medicines for children. The licence will enable other companies and organizations to re-formulate and manufacture specially designed LPV/r and r paediatric treatments for distribution in low- and middle-income countries where 99% of children with HIV in the developing world live. The MPP-AbbVie agreement supports the work of the Paediatric HIV Treatment Initiative (PHTI), a collaboration among UNITAID, MPP, the Drugs for Neglected Diseases initiative (DNDi), and the Clinton Health Access Initiative (CHAI) to spur the development of more appropriate and affordable HIV medicines for children. The PHTI is currently working with a range of stakeholders to help develop treatment options for paediatrics in the form of fixed-dose combinations (FDCs), to share patents and technology and to encourage market uptake once new FDCs are developed. The AbbVie-MPP collaboration, which marks the first time AbbVie has granted a licence for generic production of its HIV drugs, extends MPP's portfolio to eleven ARVs and one medicine for an opportunistic infection. MPP holds licences for other paediatric medicines from patent holders Bristol-Myers Squibb, Gilead Sciences and ViiV Healthcare and is in negotiations with Merck/MSD to license paediatric formulations of raltegravir. The LPV/r licence thus has broad implications as it enables the development of important FDCs with other MPP licensed medicines such as atazanavir/ritonavir (ATV/r) an alternative to LPV/r for children. The MPP-AbbVie agreement covers 102 countries of which more than 65 are classified as middle-income nations. Moreover, provisions in the agreement permit manufacture and distribution in countries where AbbVie does not hold patents, such as in India where the company has withdrawn its patent applications for both lopinavir and ritonavir.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $66.21 USD +1.86

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $160.67 USD +3.15
Bristol-Myers Squibb Co $59.15 USD -0.01
Eli Lilly & Co $70.16 USD +0.42
Gilead Sciences Inc $91.29 USD +1.84
Novo Nordisk A/S kr260.80 DKK -6.40
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 28.9x
Price/Sales 5.4x
Price/Book 22.7x
Price/Cash Flow 28.4x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.